SANUWAVE Health Inc(US:SNWV)2025-05-26 19:16Financial Performance - Revenue for Q3 2023 reached $5 million, a 19% increase compared to $4.2 million in Q3 2022[15] - Revenue for the nine months ended September 30, 2023, totaled $13.4 million, also a 19% increase compared to $11.2 million for the same period in 2022[15] - UltraMist consumables revenue increased by 24% to $3.1 million, constituting 62% of overall revenues in Q3 2023[15] - Net loss for the three months ended September 30, 2023, was $23.7 million, compared to a net loss of $1.1 million for the same period in 2022, primarily due to non-cash losses on the fair value of derivative liabilities[15] - Adjusted EBITDA loss for Q3 2023 was $0.3 million, an improvement of $1.9 million compared to a loss of $2.2 million in Q3 2022[15] Operational Highlights - 55 UltraMist systems were sold in Q3 2023, an increase from 28 in Q1 2023 and 49 in Q2 2023[15] - Gross margin was 71% for the three months ended September 30, 2023, slightly down from 72% in the same period last year[15] Future Outlook - The company anticipates Q4 2023 revenue will increase approximately 15% to 25% as compared to Q4 2022[17] Corporate Developments - In July 2023, the company issued Asset-Backed Secured Promissory Notes, receiving total proceeds of approximately $3 million[19] - SANUWAVE Health entered into a merger agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp in August 2023, with the combined company expected to trade on Nasdaq under the symbol "SNWV"[19]